Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.80 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.80 |
| ▸ | KIT | P10721 | 3/20 | 0.80 |
| ▸ | SRC | P12931 | 3/20 | 0.80 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.80 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.80 |
| ▸ | CIT | O14578 | 2/20 | 0.80 |
| ▸ | GAK | O14976 | 2/20 | 0.80 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.80 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.80 |
| ▸ | STK17B | O94768 | 2/20 | 0.80 |
| ▸ | STK10 | O94804 | 2/20 | 0.80 |
| ▸ | ABL1 | P00519 | 2/20 | 0.80 |
| ▸ | LCK | P06239 | 2/20 | 0.80 |
| ▸ | LYN | P07948 | 2/20 | 0.80 |
| ▸ | RET | P07949 | 2/20 | 0.80 |
| ▸ | MET | P08581 | 2/20 | 0.80 |
| ▸ | HCK | P08631 | 2/20 | 0.80 |
| ▸ | FGR | P09769 | 2/20 | 0.80 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21350019 | 0.97 | EGFR (0.80) | EGFRERBB2KITSRCERBB3 | |
| SCHEMBL29577833 | 0.93 | EGFR (0.92) | EGFRERBB2KITSRCERBB3 | |
| SCHEMBL28713534 | 0.93 | EGFR (0.92) | EGFRERBB2KITSRCERBB3 | |
| SCHEMBL3578798 | 0.92 | EGFR (0.77) | EGFRERBB2KITSRCERBB3 | |
| SCHEMBL19612073 | 0.92 | EGFR (0.86) | EGFRERBB2KITSRCERBB3 | |
| SCHEMBL31491114 | 0.91 | EGFR (0.87) | EGFRERBB2KITSRCERBB3 | |
| SCHEMBL31491135 | 0.90 | EGFR (0.86) | EGFRERBB2KITSRCERBB3 | |
| SCHEMBL31491130 | 0.90 | EGFR (0.86) | EGFRERBB2KITSRCERBB3 | |
| SCHEMBL31491173 | 0.90 | EGFR (0.86) | EGFRERBB2KITSRCERBB3 | |
| SCHEMBL31491119 | 0.89 | EGFR (0.85) | EGFRERBB2KITSRCERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110963972-A | Quinazoline derivative, preparation method and pharmaceutical application thereof | 苏州明锐医药科技有限公司 | 2020-04-07 | — | — | CN | claimed |
| US-7772243-B2 | 4-phenylamino-quinazolin-6-yl-amides | WARNER-LAMBERT COMPANY LLC (US) | 2010-08-10 | — | — | US | claimed |
| JP-4205757-B2 | — | — | 2009-01-07 | — | — | JP | claimed |
| JP-2007536368-A | — | — | 2007-12-13 | — | — | JP | claimed |
| EP-1746999-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | Warner-Lambert Company LLC (US) | 2007-01-31 | — | — | EP | claimed |
| WO-2005107758-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-17 | — | — | WO | claimed |
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | PFIZER INC | 2005-11-10 | — | — | US | claimed |
| EP-1265874-B1 | METHOD FOR THE PRODUCTION OF (3-CHLORO-4-FLUOROPHENYL)-[7-(3-MORPHOLIN-4-YLPROPOXY)-6-NITROQUINAZOLIN-4-YL]-AMINE OR (3-CHLORO-4-FLUOROPHENYL)-[7-(3-MORPHOLIN-4-YL-PROPOXY)-6-AMINOQUINAZOLIN-4-YL]-AMINE | GOEDECKE GMBH (DE) | 2005-06-01 | — | — | EP | claimed |
| US-20030158408-A1 | Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine | ALLY BANK, AS AGENT | 2003-08-21 | — | — | US | claimed |
| US-20030050313-A1 | METHOD FOR THE SIMPLIFIED PRODUCTION OF (3-CHLORO-4-FLOUROPHENYL)-[7-(3-MORPHOLIN-4-YL-PROPOXY)-6-NITRO-QUINAZOLINE-4YL]-AMINE OR (3-CHLORO-4-FLUOROPHENYL)-[7-(3-MORPHOLIN-4-YL-PROPOXY)-6-AMINO-QUINAZOLINE-4-YL]-AMINE | BARTH HUBERT (DE) | 2003-03-13 | — | — | US | claimed |
| EP-1265874-A2 | METHOD FOR THE SIMPLIFIED PRODUCTION OF (3-CHLORO-4-FLUORO-PHENYL)- 7-(3-MORPHOLINO-4-YL-PROPOXY)-6-NITRO-QUINAZOLINE-4-YL]-AMINE OR (3-CHLORO-4-FLUORO-PHENYL)- 7-(3-MORPHOLINO-4-YL-PROPOXY)-6-AMINO-QUINAZOLINE-4-YL]-AMINE | GÖDECKE GMBH (DE) | 2002-12-18 | — | — | EP | claimed |
| WO-2001062743-A2 | METHOD FOR THE SIMPLIFIED PRODUCTION OF (3-CHLORO-4-FLUORO-PHENYL)-[7-(3-MORPHOLINO-4-YL-PROPOXY)-6-NITRO-QUINAZOLINE-4-YL]-AMINE OR (3-CHLORO-4-FLUORO-PHENYL)-[7-(3-MORPHOLINO-4-YL-PROPOXY)-6-AMINO-QUINAZOLINE-4-YL]-AMINE | Gödecke GmbH (DE) | 2001-08-30 | — | — | WO | claimed |
| US-20230001008-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | KUMQUAT BIOSCIENCES INC. | 2023-01-05 | — | — | US | disclosed |
| WO-2021035096-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | KUMQUAT BIOSCIENCES INC. (US) | 2021-02-25 | — | — | WO | disclosed |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-9371292-B2 | Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof | SHANGHAI PHARMACEUTICALS HOLDINGS CO., LTD. (CN) | 2016-06-21 | — | — | US | disclosed |
| WO-2001062743-A2 | METHOD FOR THE SIMPLIFIED PRODUCTION OF (3-CHLORO-4-FLUORO-PHENYL)-[7-(3-MORPHOLINO-4-YL-PROPOXY)-6-NITRO-QUINAZOLINE-4-YL]-AMINE OR (3-CHLORO-4-FLUORO-PHENYL)-[7-(3-MORPHOLINO-4-YL-PROPOXY)-6-AMINO-QUINAZOLINE-4-YL]-AMINE | Gödecke GmbH (DE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062743-A2 | METHOD FOR THE SIMPLIFIED PRODUCTION OF (3-CHLORO-4-FLUORO-PHENYL)-[7-(3-MORPHOLINO-4-YL-PROPOXY)-6-NITRO-QUINAZOLINE-4-YL]-AMINE OR (3-CHLORO-4-FLUORO-PHENYL)-[7-(3-MORPHOLINO-4-YL-PROPOXY)-6-AMINO-QUINAZOLINE-4-YL]-AMINE | Gödecke GmbH (DE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062743-A2 | METHOD FOR THE SIMPLIFIED PRODUCTION OF (3-CHLORO-4-FLUORO-PHENYL)-[7-(3-MORPHOLINO-4-YL-PROPOXY)-6-NITRO-QUINAZOLINE-4-YL]-AMINE OR (3-CHLORO-4-FLUORO-PHENYL)-[7-(3-MORPHOLINO-4-YL-PROPOXY)-6-AMINO-QUINAZOLINE-4-YL]-AMINE | Gödecke GmbH (DE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2000031048-A1 | N-[4-(3-CHLORO-4-FLUORO-PHENYLAMINO)-7-(3-MORPHOLIN-4-YL-PROPOXY)-QUINAZOLIN-6-YL]-ACRYLAMIDE, AN IRREVERSIBLE INHIBITOR OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230001008-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | CD2BP2, CD47, CD74 | EGFR 1892/4885ERBB2 2230/4885KIT 2929/4885 |
| US-20030158408-A1 | Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine | MAP7, HTR7, ABL1 | EGFR 2566/4885ERBB2 709/4885KIT 246/4885 |
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | JAK1, JAK2, EDNRA | EGFR 41/4885ERBB2 8/4885KIT 2048/4885 |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | EGFR 108/4885ERBB2 132/4885KIT 4505/4885 |
| US-20030050313-A1 | METHOD FOR THE SIMPLIFIED PRODUCTION OF (3-CHLORO-4-FLOUROPHENYL)-[7-(3-MORPHOLIN-4-YL-PROPOXY)-6-NITRO-QUINAZOLINE-4YL]-AMINE OR (3-CHLORO-4-FLUOROPHENYL)-[7-(3-MORPHOLIN-4-YL-PROPOXY)-6-AMINO-QUINAZOLINE-4-YL]-AMINE | MAP7, PNMT, ABL1 | EGFR 2178/4885ERBB2 457/4885KIT 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.